Saturday, June 22, 2024

Stroke Rehabilitation Study Approved by FDA for CorTec’s Implant System

Similar articles

Stroke rehabilitation will be the focus of a study exploring the potential of cortical stimulation to enhance brain plasticity. The US Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application by the University of Washington School of Medicine to conduct an early feasibility study using CorTec’s Brain Interchange implant system. This study aims to investigate the potential of cortical stimulation in stroke rehabilitation to enhance brain plasticity by utilizing the closed-loop Brain Interchange implant system.

The Brain Interchange System is a fully implantable closed-loop brain-computer interface (BCI) that has now been cleared for human use. This technology is expected to open new avenues for the investigation of therapies for neurological diseases. CorTec’s chief technology officer, Dr. Martin Schuettler, explained, “The system is capable of interchanging information between biology and technology, between brain and computer. That’s why we call it CorTec Brain Interchange. With our system, we are providing the technological tools that are needed to develop new therapies and brain-computer interface applications.”

The IDE study, which marks the first human application of the Brain Interchange System, is planned to be conducted in collaboration with experts in the field. Principal investigator Professor Jeffrey Ojemann from the University of Washington School of Medicine, along with Professor Steven Cramer from the University of California Los Angeles and their teams, will spearhead the research. Funded by the US National Institutes of Health (NIH), the consortium’s goal is to gather initial safety data and develop and assess new therapeutic rehabilitation strategies for upper limb impairment in stroke patients.

Brain Interchange System to Revolutionize Stroke Rehabilitation with Closed-Loop Cortical Stimulation

The Brain Interchange System will deliver direct cortical electrical stimulation as part of the treatment. Patient enrollment and the inaugural implantation of the neural interfacing system are scheduled for the third quarter of 2024. This study could pave the way for innovative treatments that could significantly impact stroke rehabilitation practices.

The Brain Interchange System represents a significant advancement in brain-computer interface technology, being fully implantable and capable of operating in a closed-loop manner. This means the device can both stimulate the brain and record brain activity, allowing for real-time adjustments to the stimulation parameters based on the brain’s responses. This closed-loop capability is crucial for optimizing the therapeutic effects and minimizing potential side effects.

Dr. Martin Schuettler emphasized the importance of this technology in developing new therapies, stating, “Our system’s ability to interchange information between the brain and computer is revolutionary. It provides a platform for the development of advanced brain-computer interface applications and therapies for neurological conditions.” This sentiment underscores the potential for the Brain Interchange System to not only enhance stroke rehabilitation but also to contribute to broader applications in neurology.

Stroke Rehabilitation

NIH-Funded Study on Brain Interchange System Aims to Revolutionize Stroke Rehabilitation

The study’s principal investigators, Professor Jeffrey Ojemann and Professor Steven Cramer bring extensive expertise in neurology and stroke rehabilitation to the project. Their collaboration, supported by the NIH, aims to develop and evaluate new rehabilitation strategies that could improve outcomes for stroke patients with upper limb impairments. The focus on upper limb rehabilitation is particularly significant, as many stroke survivors experience long-term disability affecting their arms and hands, which can severely impact their daily lives.

The NIH funding underscores the importance of this research and the potential impact of the findings. By gathering initial safety data and developing therapeutic strategies, the study aims to lay the groundwork for larger clinical trials and eventual widespread adoption of the Brain Interchange System in stroke rehabilitation. Patient enrollment is a critical step in this process, and the planned implantation of the neural interfacing system in the third quarter of 2024 marks the beginning of the study’s human application phase. The outcomes of this study could lead to significant advancements in stroke rehabilitation, providing new hope for patients and potentially setting new standards for treatment practices.

You can follow our news on our Telegram and LinkedIn accounts.

In conclusion, the FDA’s approval of the IDE application for CorTec’s Brain Interchange implant system represents a major milestone in the field of stroke rehabilitation. This study will explore the potential of cortical stimulation to enhance brain plasticity, potentially leading to innovative and effective treatments for stroke patients. With the involvement of leading experts and the support of the NIH, this research has the potential to make a substantial impact on the lives of stroke survivors, paving the way for future advancements in neurological therapies.

Resource: Cortec, May 23, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article